An Evaluation of an SCCD on the Symptomatology of Painful DPN

Painful Diabetic Neuropathy Clinical Trial

Official title:

A Randomized Controlled Evaluation of the Effect of Sequential Contraction Compression Device on the Symptomatology of Painful Diabetic Neuropathy (PDN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03331614
• Other study ID #: SCN-1
• Status: Recruiting
• Phase: N/A
• First received: October 27, 2017
• Last updated: November 2, 2017
• Start date: October 15, 2017
• Est. completion date: April 30, 2018

Study information

• Verified date: October 2017
• Source: Rosenblum, Jonathan I., DPM
• Contact: Jonathan Rosenblum, DPM
• Phone: 720-744-3222
• Email: diabfootman[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a controlled trial to evaluate the efficacy of an Sequential Contraction Compression Device (SCCD) on the symptomatology of Painful Diabetic Neuropathy. Subjects will be divided into a control group where they will be monitored while continuing with their current treatment regimen and into a treatment group where they will continue with their current regimen and have SCCD therapy added. Subjects will be evaluated for Subjective Pain levels, quality of life, breakthrough drug use, sleep levels, and objectively with a Quantitative Sensory Testing device. The trial duration is 30 days.

Description:

This is a controlled trial of 30 days duration to evaluate the efficacy of an Sequential Contraction Compression Device (SCCD) on the symptomatology of Painful Diabetic Neuropathy. Subjects will have to have been on a sustained drug regimen for more than 30 days and have an average pain level of 4 on a VAS. Subjects will be divided into a control group where they will be monitored while continuing with their current treatment regimen and into a treatment group where they will continue with their current regimen and have SCCD therapy added. Patients will be asked to use the SCCD device daily on both their legs. Subjects will be evaluated for Subjective Pain levels using a Visual Analog Scale, quality of life using various questionnaires, breakthrough drug use in a daily log, sleep levels i.e. how many consecutive hours of sleep, and objectively with a Quantitative Sensory Testing device.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: April 30, 2018
• Est. primary completion date: April 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Have a current diagnosis of Type I or Type II Diabetes Mellitus

• Have a documented diagnosis of Diabetic Peripheral Neuropathy by either their Primary Care Physician or other physician treating their condition made no less than 6 months prior to initiation of the study.

• Have been on stable pain medications (no change to type, dose or frequency) for at least 1 month prior to their entry into the study.Give appropriate written informed consent prior to participation in the study

• Be between 18 and 90 years of age, inclusive, on the day the Informed Consent Form is signed

• Have an average baseline VAS score of 4 or more as assessed during the week just prior to randomization

• Be in reasonable metabolic control, exhibited by HbA1C values of less than 12% as observed by serum test results obtained within 3 months prior to the Screening Visit

• Be willing to remain on the same pain medication regimen for the duration of the study

• If subject is of childbearing potential, she must be using an acceptable method of birth control. Women not of childbearing potential are defined as either surgically sterile or post-menopausal. Post-menopausal women are defined as those women with a documented menstruation cessation for 12 consecutive months prior to signing the Informed Consent Form.

• Subject and caregiver, if applicable, must be accessible and willing to comply with all requirements of the study protocol for the duration of the study.

Exclusion Criteria:

• Clinical evidence of compromised skin (e.g., wound, infection, gangrene) on the lower legs

• Active Charcot's foot on either limb

• Malnourished as evidenced by a pre-albumin of < 11 mg/dL

• Pregnancy or lactating

• Known history of alcohol or drug abuse within the previous one year

• Previous treatment with SCCD

• Elective osseous procedures performed to either foot 30 days prior to Screening visit

• Vascular procedures performed 30 days prior to Screening Visit

• History of poor compliance to medical treatment regimens

• Conditions that may severely compromise their ability to complete the study.

• Concomitant history of Peripheral Arterial disease with an ABI of <0.5

• Chronic pain due to an etiology other than diabetic neuropathy

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Pain
• Painful Diabetic Neuropathy

Intervention

Device:
• Flowaid FA-100 SCCD
The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.

Locations

Country	Name	City	State
United States	Sean D Rosenblum DPM	Lodi	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Rosenblum, Jonathan I., DPM

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Subjective Pain	Reduction in pain as measured using a pain descriptive Visual Analog Scale (VAS). The SCCD treatment will be considered effective if the subjects treated with the SCCD demonstrate, on average, a 30% greater reduction in pain on the VAS as compared to the control subjects.	30 days
Secondary	Quantitative Sensation	1) The ability of the subject to discriminate temperature and vibration on the bottom of the foot as measured by a quantitative tool.	30 days
Secondary	Analgesic Use	4) Improvement in PDN as measured by the change in usage of prescribed regimented and breakthrough medications for analgesia	30 days
Secondary	Quality of Life	3) Improved quality of life as measured using the SF36 QOL questionnaire.	30 days